Drug Targets from Genomics - Evolving Tools for Discovery
Published August 2005
Report Overview
Drug Targets from Genomics: Evolving Tools for Discovery seeks to examine the roles omic technologies play in pharma R&D, to assess their value to pharma, and to predict their future role and value. This Report analyzes current and projected revenues from sales of omic technology-based products (reagents and consumables), which in 2004 totaled nearly $1.5 billion. Revenues are projected to increase to $2.3 billion by 2009. Also provided is a breakdown of revenues into transcriptomic, proteomic, metabolomic, and genotyping categories.
Drug Targets from Genomics: Evolving Tools for Discovery Report has the following objectives:
• To delineate the roles played by omic technologies in drug discovery and development
• To assess the value to date of omic technologies for pharma
• To predict the future value of omic technologies for pharma
• To assess the current and future value of particular applications of omic technologies for pharma
• To evaluate the role omic technologies play for individual pharmaceutical companies
Data for this Report was derived from several sources: interviews with experts in the field, discussions with technology users, the author's knowledge base, a proprietary D&MD survey, industry sources, and published reports on the technologies and their applications.
Questions Answered
• Which pharma applications of omic technologies have been most successful to date?
• Which pharma applications of omic technologies have the most promise for the future?
• To what extent has genomics become embedded in pharma R&D?
• How will pharma spending on omic technology products change in the future?
• To what extent have omic technologies proved their value for pharma?
• How have omic technologies fared in target identification?
• To what extent has SNP genotyping contributed to target identification?
• What are the prospects for omic-based toxicity prediction?
• To what extent will omic-based patient stratification be practical?
Further Information: http://www.marketreports.com/x2423